These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 3555175)

  • 21. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon.
    Gjørup T; Kelbaek H; Hartling OJ; Nielsen SL
    Am Heart J; 1986 Apr; 111(4):742-5. PubMed ID: 3513504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon.
    Wollersheim H; Thien T; Fennis J; van Elteren P; van 't Laar A
    Clin Pharmacol Ther; 1986 Aug; 40(2):219-25. PubMed ID: 3731684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.
    Gjørup T; Hartling OJ; Kelbaek H; Nielsen SL
    Eur J Clin Pharmacol; 1986; 31(4):387-9. PubMed ID: 3816916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.
    Rodeheffer RJ; Rommer JA; Wigley F; Smith CR
    N Engl J Med; 1983 Apr; 308(15):880-3. PubMed ID: 6339921
    [No Abstract]   [Full Text] [Related]  

  • 26. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon.
    Challenor VF; Waller DG; Hayward RA; Griffin MJ; Roath OS
    Angiology; 1989 Feb; 40(2):122-8. PubMed ID: 2644877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.
    Ettinger WH; Wise RA; Schaffhauser D; Wigley FM
    Am J Med; 1984 Sep; 77(3):451-6. PubMed ID: 6540986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Cardiol; 1985 Jan; 55(3):154B-157B. PubMed ID: 3881908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nicardipine in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkès CJ
    Arthritis Rheum; 1987 May; 30(5):598. PubMed ID: 3593442
    [No Abstract]   [Full Text] [Related]  

  • 31. Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study.
    White CJ; Phillips WA; Abrahams LA; Watson TD; Singleton PT
    Am J Med; 1986 Apr; 80(4):623-5. PubMed ID: 3515931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind randomized trial of nitroderm TTS in the treatment of Raynaud's phenomenon.
    Nahir AM; Schapira D; Scharf Y
    Isr J Med Sci; 1986 Feb; 22(2):139-42. PubMed ID: 3081460
    [No Abstract]   [Full Text] [Related]  

  • 35. Isosorbide dinitrate ointment in Raynaud's disease.
    Diehm C; Müller-Bühl U; Mörl H
    Z Kardiol; 1983; 72 Suppl 3():185-7. PubMed ID: 6364591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triiodothyronine treatment for Raynaud's phenomenon: a controlled trial.
    Dessein PH; Morrison RC; Lamparelli RD; van der Merwe CA
    J Rheumatol; 1990 Aug; 17(8):1025-8. PubMed ID: 2213778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of Raynaud's syndrome with calcium entry blockers].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ; Mariz HA; Andrade LE; Kayser C
    Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.